Pixalate’s ratings system ranks sellers based on their direct relationships with premium publishers (sustainability), ...

Financially, Verve has a market cap of $475mn, cash balance of $540mn, and a cash runway of 7-8 quarters. Find out my ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 25.48% ...

EXCLUSIVE: Academy Award-winning NYC studio Believe Entertainment Group has signed with Verve for representation. The news ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Verve Therapeutics (VERV – Research Report) and decreased the price target to $14.00 from $15.00. Mitchell Kapoor has ...

H.C. Wainwright lowered the firm’s price target on Verve Therapeutics (VERV) to $14 from $15 and keeps a Buy rating on the shares after the company announced that it has dosed seven patients ...